DK3083605T3 - Fluorphenylpyrazolforbindelser - Google Patents
Fluorphenylpyrazolforbindelser Download PDFInfo
- Publication number
- DK3083605T3 DK3083605T3 DK14827909.4T DK14827909T DK3083605T3 DK 3083605 T3 DK3083605 T3 DK 3083605T3 DK 14827909 T DK14827909 T DK 14827909T DK 3083605 T3 DK3083605 T3 DK 3083605T3
- Authority
- DK
- Denmark
- Prior art keywords
- mmol
- compound
- give
- fluorophenyl
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (13)
1. Forbindelse, som er
hvor X er udvalgt fra gruppen bestående af
R er udvalgt fra gruppen bestående af H og CH3; R1 er udvalgt fra gruppen bestående af H, CH3, F, Cl, OCFI3, C(0)0FI, C(0)NH2 og
eller et farmaceutisk acceptabelt salt deraf.
2. Forbindelse eller farmaceutisk acceptabelt salt deraf ifølge krav 1, hvor X er
3. Forbindelse eller farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 2, hvor X er
4. Forbindelse eller salt ifølge et af kravene 1 til 3, hvor R1 er udvalgt fra gruppen bestående af H, F og CFI3.
5. Forbindelse eller salt ifølge et af kravene 1 til 3, hvor R1 er
6. Forbindelse ifølge et af kravene 1 til 4, hvor forbindelsen er [3-[[3-(4-fluorphenyl)-1 H-pyrazol-4-yl]oxy]phenyl]methylurinstof eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse eller salt ifølge et af kravene 1 til 2, hvor X er
8. Forbindelse eller salt ifølge et af kravene 1,2, eller 7, hvor R er CFI3.
9. Forbindelse ifølge et af kravene 1, 2, 7 eller 8, hvor forbindelsen er [6-[[3-(4-fluorphenyl)-1 H-pyrazol-4-yl]oxy]-5-methyl-2-pyridyl]methylurinstof eller et farmaceutisk acceptabelt salt deraf.
10. Forbindelse eller farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 9 til anvendelse inden for terapi.
11. Forbindelse eller et farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 9 til anvendelse ved behandlingen af obesitet.
12. Forbindelse eller et farmaceutisk acceptabelt salt deraf ifølge et af kravene 1 til 9 til anvendelse ved terapeutisk vægttab.
13. Farmaceutisk sammensætning omfattende en forbindelse ifølge et af kravene 1 til 9 eller et farmaceutisk acceptabelt salt deraf og mindst et far- maceutisk acceptabelt bærestof, fortyndingsmiddel eller hjælpestof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2013/089987 WO2015089800A1 (en) | 2013-12-19 | 2013-12-19 | Fluorophenyl pyrazol compounds |
PCT/US2014/069785 WO2015094913A1 (en) | 2013-12-19 | 2014-12-11 | Fluorophenyl pyrazol compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3083605T3 true DK3083605T3 (da) | 2018-03-12 |
Family
ID=52355187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14827909.4T DK3083605T3 (da) | 2013-12-19 | 2014-12-11 | Fluorphenylpyrazolforbindelser |
Country Status (23)
Country | Link |
---|---|
US (1) | US9499490B2 (da) |
EP (1) | EP3083605B1 (da) |
JP (1) | JP6190067B2 (da) |
KR (1) | KR101827660B1 (da) |
CN (1) | CN105814039B (da) |
AU (1) | AU2014366436B2 (da) |
BR (1) | BR112016011778A8 (da) |
CA (1) | CA2929563C (da) |
DK (1) | DK3083605T3 (da) |
EA (1) | EA029058B1 (da) |
ES (1) | ES2664418T3 (da) |
HR (1) | HRP20180618T1 (da) |
HU (1) | HUE039102T2 (da) |
LT (1) | LT3083605T (da) |
MX (1) | MX2016007985A (da) |
NO (1) | NO3083605T3 (da) |
PL (1) | PL3083605T3 (da) |
PT (1) | PT3083605T (da) |
RS (1) | RS57071B1 (da) |
SA (1) | SA516371323B1 (da) |
SI (1) | SI3083605T1 (da) |
TR (1) | TR201802981T4 (da) |
WO (2) | WO2015089800A1 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
WO2016066664A1 (en) * | 2014-10-31 | 2016-05-06 | F. Hoffmann-La Roche Ag | New pyridinyloxy- and phenyloxy-pyrazolyl compounds |
WO2016131198A1 (en) | 2015-02-18 | 2016-08-25 | Eli Lilly And Company | Pyrazole compounds |
WO2016201662A1 (en) * | 2015-06-18 | 2016-12-22 | Eli Lilly And Company | Fluoropyridyl pyrazol compounds |
CN109096194B (zh) * | 2018-10-09 | 2022-02-08 | 湖南师范大学 | 一种双胍衍生物、药物组合物、制备方法和用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7989400A (en) * | 1999-10-01 | 2001-05-10 | Smithkline Beecham Corporation | Compounds and methods |
AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
JP2004525942A (ja) * | 2001-03-29 | 2004-08-26 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
US20040192914A1 (en) * | 2001-10-12 | 2004-09-30 | Kallander Lara S | Compounds and methods |
AU2002359694A1 (en) * | 2001-12-14 | 2003-06-30 | Smithkline Beecham Corporation | Compounds and methods |
AU2003251739A1 (en) | 2002-07-02 | 2004-01-23 | Schering Corporation | New neuropeptide y y5 receptor antagonists |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
DE102004049078A1 (de) * | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
US20120010290A1 (en) * | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
TW201245155A (en) | 2010-09-01 | 2012-11-16 | Du Pont | Fungicidal pyrazoles |
WO2012090219A2 (en) * | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors |
EP2702042A1 (en) * | 2011-04-28 | 2014-03-05 | Bristol-Myers Squibb Company | Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators |
TWI582083B (zh) | 2014-10-07 | 2017-05-11 | 美國禮來大藥廠 | 胺基吡啶基氧基吡唑化合物 |
-
2013
- 2013-12-19 WO PCT/CN2013/089987 patent/WO2015089800A1/en active Application Filing
-
2014
- 2014-12-11 WO PCT/US2014/069785 patent/WO2015094913A1/en active Application Filing
- 2014-12-11 ES ES14827909.4T patent/ES2664418T3/es active Active
- 2014-12-11 JP JP2016540485A patent/JP6190067B2/ja not_active Expired - Fee Related
- 2014-12-11 BR BR112016011778A patent/BR112016011778A8/pt not_active IP Right Cessation
- 2014-12-11 RS RS20180398A patent/RS57071B1/sr unknown
- 2014-12-11 SI SI201430663T patent/SI3083605T1/en unknown
- 2014-12-11 MX MX2016007985A patent/MX2016007985A/es unknown
- 2014-12-11 KR KR1020167015900A patent/KR101827660B1/ko active IP Right Grant
- 2014-12-11 TR TR2018/02981T patent/TR201802981T4/tr unknown
- 2014-12-11 EP EP14827909.4A patent/EP3083605B1/en active Active
- 2014-12-11 AU AU2014366436A patent/AU2014366436B2/en not_active Ceased
- 2014-12-11 EA EA201690924A patent/EA029058B1/ru not_active IP Right Cessation
- 2014-12-11 HU HUE14827909A patent/HUE039102T2/hu unknown
- 2014-12-11 CA CA2929563A patent/CA2929563C/en not_active Expired - Fee Related
- 2014-12-11 PT PT148279094T patent/PT3083605T/pt unknown
- 2014-12-11 NO NO14827909A patent/NO3083605T3/no unknown
- 2014-12-11 DK DK14827909.4T patent/DK3083605T3/da active
- 2014-12-11 LT LTEP14827909.4T patent/LT3083605T/lt unknown
- 2014-12-11 PL PL14827909T patent/PL3083605T3/pl unknown
- 2014-12-11 US US15/037,344 patent/US9499490B2/en active Active
- 2014-12-11 CN CN201480068824.0A patent/CN105814039B/zh active Active
-
2016
- 2016-06-14 SA SA516371323A patent/SA516371323B1/ar unknown
-
2018
- 2018-04-18 HR HRP20180618TT patent/HRP20180618T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
EP3083605B1 (en) | 2018-02-21 |
CN105814039B (zh) | 2018-07-17 |
CA2929563A1 (en) | 2015-06-25 |
KR101827660B1 (ko) | 2018-02-08 |
TR201802981T4 (tr) | 2018-03-21 |
SA516371323B1 (ar) | 2018-04-24 |
PT3083605T (pt) | 2018-03-01 |
HRP20180618T1 (hr) | 2018-07-13 |
JP2016540801A (ja) | 2016-12-28 |
ES2664418T3 (es) | 2018-04-19 |
PL3083605T3 (pl) | 2018-07-31 |
CA2929563C (en) | 2018-05-15 |
WO2015094913A1 (en) | 2015-06-25 |
EA029058B1 (ru) | 2018-02-28 |
BR112016011778A2 (pt) | 2017-08-08 |
US20160289195A1 (en) | 2016-10-06 |
BR112016011778A8 (pt) | 2018-01-30 |
RS57071B1 (sr) | 2018-06-29 |
EP3083605A1 (en) | 2016-10-26 |
WO2015089800A1 (en) | 2015-06-25 |
MX2016007985A (es) | 2016-09-09 |
HUE039102T2 (hu) | 2018-12-28 |
US9499490B2 (en) | 2016-11-22 |
JP6190067B2 (ja) | 2017-08-30 |
AU2014366436A1 (en) | 2016-05-19 |
NO3083605T3 (da) | 2018-07-21 |
SI3083605T1 (en) | 2018-04-30 |
LT3083605T (lt) | 2018-04-10 |
KR20160075827A (ko) | 2016-06-29 |
AU2014366436B2 (en) | 2017-08-24 |
EA201690924A1 (ru) | 2016-09-30 |
CN105814039A (zh) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020114482A1 (zh) | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 | |
DK3083605T3 (da) | Fluorphenylpyrazolforbindelser | |
JP5933746B2 (ja) | イミダゾリジンジオン系化合物およびその用途 | |
JP2022525186A (ja) | Tead転写因子新規小分子阻害剤 | |
CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
Yang et al. | 4, 6-Substituted-1H-Indazoles as potent IDO1/TDO dual inhibitors | |
JP6918378B2 (ja) | CaMKII阻害剤及びその使用 | |
JPWO2020009156A1 (ja) | ビアリールエーテル型キナゾリン誘導体 | |
Huang et al. | Structure-guided design of novel Trypanosoma brucei methionyl-tRNA synthetase inhibitors | |
EP2914597B1 (en) | Pyrazolopyridine derivatives as ttx-s blockers | |
CN109400632B (zh) | 一种含n-甲基依诺沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用 | |
EP3259256B1 (en) | Compounds and methods for inducing browning of white adipose tissue | |
US20210061789A1 (en) | Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor | |
EP1944024A1 (en) | O-substituted aniline derivative and antioxidant drug | |
JP2017521439A (ja) | 新規なトリアゾロピリミジノン又はトリアゾロピリジノン誘導体、及びこれらの用途 | |
CN109438472B (zh) | 一种含n-甲基加替沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用 | |
CN109438482B (zh) | 一种含芦氟沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用 | |
CN105814018B (zh) | 新型脲类化合物、制备方法及其用途 | |
CN109438481B (zh) | 一种含n-甲基莫西沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用 | |
US11401261B2 (en) | 2-heteroaryl aminoquinazolinone derivative | |
CN109369674B (zh) | 一种含左氧氟沙星的双-氟喹诺酮基噁二唑脲类衍生物及其制备方法和应用 | |
EP2527335B1 (en) | Triazole compounds as anti-inflammatory agents | |
Choi et al. | Synthesis and biological evaluation of novel GSK-3β inhibitors as anticancer agents | |
DK2802563T3 (da) | Nye heteroarylamidderivater der har antiandrogene egenskaber | |
WO2016205031A1 (en) | Fluoropyridyl pyrazol compounds |